nodes	percent_of_prediction	percent_of_DWPC	metapath
Bortezomib—Vitamin B12 deficiency—Metformin—metabolic syndrome X	0.0382	0.136	CcSEcCtD
Bortezomib—Tonsillitis—Metformin—metabolic syndrome X	0.0159	0.0565	CcSEcCtD
Bortezomib—Angina unstable—Metformin—metabolic syndrome X	0.0159	0.0565	CcSEcCtD
Bortezomib—Abnormal faeces—Metformin—metabolic syndrome X	0.014	0.05	CcSEcCtD
Bortezomib—CTSG—cardiovascular system—metabolic syndrome X	0.013	0.0561	CbGeAlD
Bortezomib—PSMA1—cardiovascular system—metabolic syndrome X	0.0125	0.0539	CbGeAlD
Bortezomib—CTSG—adipose tissue—metabolic syndrome X	0.0115	0.0495	CbGeAlD
Bortezomib—PSMA1—adipose tissue—metabolic syndrome X	0.011	0.0475	CbGeAlD
Bortezomib—PSMD2—cardiovascular system—metabolic syndrome X	0.00928	0.0401	CbGeAlD
Bortezomib—PSMD1—adipose tissue—metabolic syndrome X	0.00924	0.0399	CbGeAlD
Bortezomib—PSMD2—kidney—metabolic syndrome X	0.00908	0.0392	CbGeAlD
Bortezomib—PSMD2—adipose tissue—metabolic syndrome X	0.00818	0.0353	CbGeAlD
Bortezomib—PSMB8—adipose tissue—metabolic syndrome X	0.00813	0.0351	CbGeAlD
Bortezomib—PSMA1—liver—metabolic syndrome X	0.00772	0.0333	CbGeAlD
Bortezomib—Azotaemia—Metformin—metabolic syndrome X	0.00752	0.0268	CcSEcCtD
Bortezomib—Acidosis—Metformin—metabolic syndrome X	0.00723	0.0258	CcSEcCtD
Bortezomib—PSMB5—adipose tissue—metabolic syndrome X	0.00718	0.031	CbGeAlD
Bortezomib—PSMB1—cardiovascular system—metabolic syndrome X	0.00712	0.0307	CbGeAlD
Bortezomib—PSMB1—kidney—metabolic syndrome X	0.00697	0.0301	CbGeAlD
Bortezomib—PSMB2—cardiovascular system—metabolic syndrome X	0.00695	0.03	CbGeAlD
Bortezomib—PSMB2—kidney—metabolic syndrome X	0.0068	0.0293	CbGeAlD
Bortezomib—PSMD1—liver—metabolic syndrome X	0.00648	0.028	CbGeAlD
Bortezomib—Respiratory distress—Metformin—metabolic syndrome X	0.0063	0.0225	CcSEcCtD
Bortezomib—PSMB1—adipose tissue—metabolic syndrome X	0.00628	0.0271	CbGeAlD
Bortezomib—Nail disorder—Metformin—metabolic syndrome X	0.00617	0.022	CcSEcCtD
Bortezomib—PSMB2—adipose tissue—metabolic syndrome X	0.00613	0.0264	CbGeAlD
Bortezomib—SLC31A1—kidney—metabolic syndrome X	0.00589	0.0254	CbGeAlD
Bortezomib—PSMD2—liver—metabolic syndrome X	0.00574	0.0248	CbGeAlD
Bortezomib—PSMB8—liver—metabolic syndrome X	0.0057	0.0246	CbGeAlD
Bortezomib—SLC31A1—adipose tissue—metabolic syndrome X	0.00531	0.0229	CbGeAlD
Bortezomib—Fungal infection—Metformin—metabolic syndrome X	0.00519	0.0185	CcSEcCtD
Bortezomib—PTGS1—artery—metabolic syndrome X	0.00517	0.0223	CbGeAlD
Bortezomib—PSMB5—liver—metabolic syndrome X	0.00504	0.0217	CbGeAlD
Bortezomib—Rhinorrhoea—Metformin—metabolic syndrome X	0.00494	0.0176	CcSEcCtD
Bortezomib—Rigors—Metformin—metabolic syndrome X	0.0049	0.0175	CcSEcCtD
Bortezomib—Blood disorder—Metformin—metabolic syndrome X	0.00479	0.0171	CcSEcCtD
Bortezomib—Contusion—Metformin—metabolic syndrome X	0.00459	0.0164	CcSEcCtD
Bortezomib—Chest discomfort—Metformin—metabolic syndrome X	0.00453	0.0161	CcSEcCtD
Bortezomib—PSMB1—liver—metabolic syndrome X	0.0044	0.019	CbGeAlD
Bortezomib—PTGS1—endothelium—metabolic syndrome X	0.00436	0.0188	CbGeAlD
Bortezomib—PSMB2—liver—metabolic syndrome X	0.0043	0.0185	CbGeAlD
Bortezomib—PTGS1—blood vessel—metabolic syndrome X	0.00402	0.0174	CbGeAlD
Bortezomib—Neuropathy—Metformin—metabolic syndrome X	0.00376	0.0134	CcSEcCtD
Bortezomib—SLC31A1—liver—metabolic syndrome X	0.00372	0.0161	CbGeAlD
Bortezomib—Renal impairment—Metformin—metabolic syndrome X	0.00305	0.0109	CcSEcCtD
Bortezomib—Lethargy—Metformin—metabolic syndrome X	0.00297	0.0106	CcSEcCtD
Bortezomib—Pain in extremity—Metformin—metabolic syndrome X	0.00291	0.0104	CcSEcCtD
Bortezomib—Migraine—Metformin—metabolic syndrome X	0.00286	0.0102	CcSEcCtD
Bortezomib—Nateglinide—PPARG—metabolic syndrome X	0.00273	0.727	CrCbGaD
Bortezomib—Dehydration—Metformin—metabolic syndrome X	0.0027	0.00964	CcSEcCtD
Bortezomib—Abdominal pain upper—Metformin—metabolic syndrome X	0.00265	0.00947	CcSEcCtD
Bortezomib—Breast disorder—Metformin—metabolic syndrome X	0.00263	0.00937	CcSEcCtD
Bortezomib—Cramp muscle—Metformin—metabolic syndrome X	0.00262	0.00934	CcSEcCtD
Bortezomib—Nasopharyngitis—Metformin—metabolic syndrome X	0.0026	0.00927	CcSEcCtD
Bortezomib—Abdominal distension—Metformin—metabolic syndrome X	0.00253	0.00902	CcSEcCtD
Bortezomib—Influenza—Metformin—metabolic syndrome X	0.00251	0.00896	CcSEcCtD
Bortezomib—Pancreatitis—Metformin—metabolic syndrome X	0.00246	0.00879	CcSEcCtD
Bortezomib—Angina pectoris—Metformin—metabolic syndrome X	0.00245	0.00873	CcSEcCtD
Bortezomib—Abdominal discomfort—Metformin—metabolic syndrome X	0.00241	0.00859	CcSEcCtD
Bortezomib—Neutropenia—Metformin—metabolic syndrome X	0.00235	0.00838	CcSEcCtD
Bortezomib—Upper respiratory tract infection—Metformin—metabolic syndrome X	0.00233	0.00833	CcSEcCtD
Bortezomib—Infestation—Metformin—metabolic syndrome X	0.00224	0.00799	CcSEcCtD
Bortezomib—Infestation NOS—Metformin—metabolic syndrome X	0.00224	0.00799	CcSEcCtD
Bortezomib—Neuropathy peripheral—Metformin—metabolic syndrome X	0.0022	0.00783	CcSEcCtD
Bortezomib—CYP2C8—kidney—metabolic syndrome X	0.00217	0.00935	CbGeAlD
Bortezomib—Hepatobiliary disease—Metformin—metabolic syndrome X	0.00212	0.00756	CcSEcCtD
Bortezomib—Bradycardia—Metformin—metabolic syndrome X	0.00205	0.0073	CcSEcCtD
Bortezomib—Hepatitis—Metformin—metabolic syndrome X	0.00201	0.00717	CcSEcCtD
Bortezomib—Hypoaesthesia—Metformin—metabolic syndrome X	0.002	0.00714	CcSEcCtD
Bortezomib—CYP1A1—kidney—metabolic syndrome X	0.002	0.00863	CbGeAlD
Bortezomib—Oedema peripheral—Metformin—metabolic syndrome X	0.00198	0.00707	CcSEcCtD
Bortezomib—Connective tissue disorder—Metformin—metabolic syndrome X	0.00198	0.00705	CcSEcCtD
Bortezomib—CYP2C9—cardiovascular system—metabolic syndrome X	0.00197	0.00849	CbGeAlD
Bortezomib—Eye disorder—Metformin—metabolic syndrome X	0.00188	0.0067	CcSEcCtD
Bortezomib—Cardiac disorder—Metformin—metabolic syndrome X	0.00187	0.00666	CcSEcCtD
Bortezomib—Flushing—Metformin—metabolic syndrome X	0.00187	0.00666	CcSEcCtD
Bortezomib—Angiopathy—Metformin—metabolic syndrome X	0.00182	0.00651	CcSEcCtD
Bortezomib—Immune system disorder—Metformin—metabolic syndrome X	0.00182	0.00648	CcSEcCtD
Bortezomib—Mediastinal disorder—Metformin—metabolic syndrome X	0.00181	0.00646	CcSEcCtD
Bortezomib—Chills—Metformin—metabolic syndrome X	0.0018	0.00644	CcSEcCtD
Bortezomib—CYP1A1—adipose tissue—metabolic syndrome X	0.0018	0.00778	CbGeAlD
Bortezomib—PTGS1—cardiovascular system—metabolic syndrome X	0.0018	0.00775	CbGeAlD
Bortezomib—PTGS1—kidney—metabolic syndrome X	0.00176	0.00758	CbGeAlD
Bortezomib—Malnutrition—Metformin—metabolic syndrome X	0.00175	0.00624	CcSEcCtD
Bortezomib—Erythema—Metformin—metabolic syndrome X	0.00175	0.00624	CcSEcCtD
Bortezomib—Flatulence—Metformin—metabolic syndrome X	0.00172	0.00615	CcSEcCtD
Bortezomib—Dysgeusia—Metformin—metabolic syndrome X	0.00171	0.00611	CcSEcCtD
Bortezomib—Muscle spasms—Metformin—metabolic syndrome X	0.00168	0.006	CcSEcCtD
Bortezomib—Vision blurred—Metformin—metabolic syndrome X	0.00165	0.00588	CcSEcCtD
Bortezomib—Tremor—Metformin—metabolic syndrome X	0.00164	0.00585	CcSEcCtD
Bortezomib—Ill-defined disorder—Metformin—metabolic syndrome X	0.00162	0.00579	CcSEcCtD
Bortezomib—PTGS1—adipose tissue—metabolic syndrome X	0.00158	0.00683	CbGeAlD
Bortezomib—Malaise—Metformin—metabolic syndrome X	0.00158	0.00563	CcSEcCtD
Bortezomib—Syncope—Metformin—metabolic syndrome X	0.00157	0.0056	CcSEcCtD
Bortezomib—CYP2C19—liver—metabolic syndrome X	0.00157	0.00677	CbGeAlD
Bortezomib—Palpitations—Metformin—metabolic syndrome X	0.00155	0.00552	CcSEcCtD
Bortezomib—Loss of consciousness—Metformin—metabolic syndrome X	0.00154	0.00549	CcSEcCtD
Bortezomib—Hypertension—Metformin—metabolic syndrome X	0.00151	0.00539	CcSEcCtD
Bortezomib—Myalgia—Metformin—metabolic syndrome X	0.00149	0.00532	CcSEcCtD
Bortezomib—Chest pain—Metformin—metabolic syndrome X	0.00149	0.00532	CcSEcCtD
Bortezomib—Unspecified disorder of skin and subcutaneous tissue—Metformin—metabolic syndrome X	0.00148	0.00528	CcSEcCtD
Bortezomib—Discomfort—Metformin—metabolic syndrome X	0.00147	0.00525	CcSEcCtD
Bortezomib—CYP3A4—kidney—metabolic syndrome X	0.00147	0.00633	CbGeAlD
Bortezomib—CYP2D6—kidney—metabolic syndrome X	0.00144	0.00623	CbGeAlD
Bortezomib—Oedema—Metformin—metabolic syndrome X	0.00143	0.0051	CcSEcCtD
Bortezomib—Infection—Metformin—metabolic syndrome X	0.00142	0.00506	CcSEcCtD
Bortezomib—Shock—Metformin—metabolic syndrome X	0.00141	0.00501	CcSEcCtD
Bortezomib—Nervous system disorder—Metformin—metabolic syndrome X	0.0014	0.005	CcSEcCtD
Bortezomib—Thrombocytopenia—Metformin—metabolic syndrome X	0.0014	0.00499	CcSEcCtD
Bortezomib—Skin disorder—Metformin—metabolic syndrome X	0.00139	0.00495	CcSEcCtD
Bortezomib—Hyperhidrosis—Metformin—metabolic syndrome X	0.00138	0.00493	CcSEcCtD
Bortezomib—CYP2C8—liver—metabolic syndrome X	0.00137	0.00591	CbGeAlD
Bortezomib—Anorexia—Metformin—metabolic syndrome X	0.00136	0.00486	CcSEcCtD
Bortezomib—Hypotension—Metformin—metabolic syndrome X	0.00133	0.00476	CcSEcCtD
Bortezomib—Musculoskeletal discomfort—Metformin—metabolic syndrome X	0.0013	0.00464	CcSEcCtD
Bortezomib—Paraesthesia—Metformin—metabolic syndrome X	0.00128	0.00458	CcSEcCtD
Bortezomib—CYP1A2—liver—metabolic syndrome X	0.00128	0.00553	CbGeAlD
Bortezomib—Dyspnoea—Metformin—metabolic syndrome X	0.00127	0.00454	CcSEcCtD
Bortezomib—CYP1A1—liver—metabolic syndrome X	0.00126	0.00546	CbGeAlD
Bortezomib—Dyspepsia—Metformin—metabolic syndrome X	0.00126	0.00449	CcSEcCtD
Bortezomib—Decreased appetite—Metformin—metabolic syndrome X	0.00124	0.00443	CcSEcCtD
Bortezomib—Gastrointestinal disorder—Metformin—metabolic syndrome X	0.00123	0.0044	CcSEcCtD
Bortezomib—Fatigue—Metformin—metabolic syndrome X	0.00123	0.00439	CcSEcCtD
Bortezomib—Constipation—Metformin—metabolic syndrome X	0.00122	0.00436	CcSEcCtD
Bortezomib—CYP2C9—liver—metabolic syndrome X	0.00122	0.00525	CbGeAlD
Bortezomib—Feeling abnormal—Metformin—metabolic syndrome X	0.00118	0.0042	CcSEcCtD
Bortezomib—Gastrointestinal pain—Metformin—metabolic syndrome X	0.00117	0.00417	CcSEcCtD
Bortezomib—Urticaria—Metformin—metabolic syndrome X	0.00113	0.00405	CcSEcCtD
Bortezomib—Abdominal pain—Metformin—metabolic syndrome X	0.00113	0.00403	CcSEcCtD
Bortezomib—Nateglinide—ALB—metabolic syndrome X	0.00103	0.273	CrCbGaD
Bortezomib—Asthenia—Metformin—metabolic syndrome X	0.00102	0.00366	CcSEcCtD
Bortezomib—Pruritus—Metformin—metabolic syndrome X	0.00101	0.00361	CcSEcCtD
Bortezomib—Diarrhoea—Metformin—metabolic syndrome X	0.000977	0.00349	CcSEcCtD
Bortezomib—Dizziness—Metformin—metabolic syndrome X	0.000945	0.00337	CcSEcCtD
Bortezomib—CYP3A4—liver—metabolic syndrome X	0.000927	0.004	CbGeAlD
Bortezomib—CYP2D6—liver—metabolic syndrome X	0.000913	0.00394	CbGeAlD
Bortezomib—Vomiting—Metformin—metabolic syndrome X	0.000908	0.00324	CcSEcCtD
Bortezomib—Rash—Metformin—metabolic syndrome X	0.000901	0.00321	CcSEcCtD
Bortezomib—Dermatitis—Metformin—metabolic syndrome X	0.0009	0.00321	CcSEcCtD
Bortezomib—Headache—Metformin—metabolic syndrome X	0.000895	0.00319	CcSEcCtD
Bortezomib—Nausea—Metformin—metabolic syndrome X	0.000849	0.00303	CcSEcCtD
Bortezomib—CYP1A2—Metabolism—PLA2G6—metabolic syndrome X	3.48e-05	7.19e-05	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism of lipids and lipoproteins—PPARA—metabolic syndrome X	3.46e-05	7.14e-05	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—APOA5—metabolic syndrome X	3.45e-05	7.12e-05	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—FABP4—metabolic syndrome X	3.44e-05	7.11e-05	CbGpPWpGaD
Bortezomib—PTGS1—Metabolism—PPARA—metabolic syndrome X	3.43e-05	7.07e-05	CbGpPWpGaD
Bortezomib—PSMA1—Signaling Pathways—TGFB1—metabolic syndrome X	3.4e-05	7.02e-05	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—NAMPT—metabolic syndrome X	3.39e-05	7e-05	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—SCARB1—metabolic syndrome X	3.39e-05	6.99e-05	CbGpPWpGaD
Bortezomib—PSMD1—Signaling Pathways—TGFB1—metabolic syndrome X	3.38e-05	6.99e-05	CbGpPWpGaD
Bortezomib—PSMA1—Disease—AKT1—metabolic syndrome X	3.37e-05	6.97e-05	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism—GOT1—metabolic syndrome X	3.37e-05	6.96e-05	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism—GGT1—metabolic syndrome X	3.37e-05	6.96e-05	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—LIPC—metabolic syndrome X	3.37e-05	6.96e-05	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—GCK—metabolic syndrome X	3.37e-05	6.96e-05	CbGpPWpGaD
Bortezomib—PSMD2—Signaling Pathways—TGFB1—metabolic syndrome X	3.37e-05	6.95e-05	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—NAMPT—metabolic syndrome X	3.36e-05	6.94e-05	CbGpPWpGaD
Bortezomib—PSMD1—Disease—AKT1—metabolic syndrome X	3.36e-05	6.93e-05	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—APOC3—metabolic syndrome X	3.35e-05	6.92e-05	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism of lipids and lipoproteins—AGT—metabolic syndrome X	3.35e-05	6.91e-05	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism of lipids and lipoproteins—PPARG—metabolic syndrome X	3.34e-05	6.9e-05	CbGpPWpGaD
Bortezomib—PSMD2—Disease—AKT1—metabolic syndrome X	3.34e-05	6.9e-05	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—LIPC—metabolic syndrome X	3.34e-05	6.9e-05	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—GCK—metabolic syndrome X	3.34e-05	6.9e-05	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—APOC3—metabolic syndrome X	3.32e-05	6.86e-05	CbGpPWpGaD
Bortezomib—PTGS1—Metabolism—AGT—metabolic syndrome X	3.32e-05	6.85e-05	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism of lipids and lipoproteins—ALB—metabolic syndrome X	3.3e-05	6.81e-05	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—SREBF1—metabolic syndrome X	3.29e-05	6.79e-05	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism of lipids and lipoproteins—APOE—metabolic syndrome X	3.28e-05	6.77e-05	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—HSD11B1—metabolic syndrome X	3.26e-05	6.74e-05	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—CETP—metabolic syndrome X	3.25e-05	6.71e-05	CbGpPWpGaD
Bortezomib—PTGS1—Metabolism—APOE—metabolic syndrome X	3.25e-05	6.71e-05	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism of lipids and lipoproteins—APOA1—metabolic syndrome X	3.24e-05	6.69e-05	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism of lipids and lipoproteins—PTGS2—metabolic syndrome X	3.23e-05	6.67e-05	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—CETP—metabolic syndrome X	3.22e-05	6.66e-05	CbGpPWpGaD
Bortezomib—PTGS1—Metabolism—APOA1—metabolic syndrome X	3.21e-05	6.64e-05	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—TRIB3—metabolic syndrome X	3.2e-05	6.62e-05	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—HMGCR—metabolic syndrome X	3.2e-05	6.6e-05	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—GOT2—metabolic syndrome X	3.2e-05	6.6e-05	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism—ABCA1—metabolic syndrome X	3.19e-05	6.59e-05	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism—SLC2A4—metabolic syndrome X	3.19e-05	6.59e-05	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—SCARB1—metabolic syndrome X	3.11e-05	6.43e-05	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism—GOT1—metabolic syndrome X	3.09e-05	6.39e-05	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism—GGT1—metabolic syndrome X	3.09e-05	6.39e-05	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—SCARB1—metabolic syndrome X	3.09e-05	6.37e-05	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—SREBF1—metabolic syndrome X	3.02e-05	6.24e-05	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism of lipids and lipoproteins—ALB—metabolic syndrome X	3.01e-05	6.21e-05	CbGpPWpGaD
Bortezomib—PSMB5—Immune System—IL6—metabolic syndrome X	3e-05	6.2e-05	CbGpPWpGaD
Bortezomib—PSMB1—Immune System—IL6—metabolic syndrome X	3e-05	6.2e-05	CbGpPWpGaD
Bortezomib—PSMB2—Immune System—IL6—metabolic syndrome X	3e-05	6.2e-05	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—SREBF1—metabolic syndrome X	3e-05	6.19e-05	CbGpPWpGaD
Bortezomib—PSMB8—Immune System—IL6—metabolic syndrome X	2.96e-05	6.11e-05	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—HMGCR—metabolic syndrome X	2.94e-05	6.07e-05	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—GOT2—metabolic syndrome X	2.94e-05	6.07e-05	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—GOT2—metabolic syndrome X	2.92e-05	6.02e-05	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—HMGCR—metabolic syndrome X	2.92e-05	6.02e-05	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—G6PD—metabolic syndrome X	2.91e-05	6e-05	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—metabolic syndrome X	2.88e-05	5.96e-05	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—NAMPT—metabolic syndrome X	2.87e-05	5.93e-05	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism—APOB—metabolic syndrome X	2.86e-05	5.91e-05	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism of lipids and lipoproteins—PPARG—metabolic syndrome X	2.86e-05	5.9e-05	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—LIPC—metabolic syndrome X	2.86e-05	5.9e-05	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—GCK—metabolic syndrome X	2.86e-05	5.9e-05	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—ABCA1—metabolic syndrome X	2.85e-05	5.88e-05	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—SLC2A4—metabolic syndrome X	2.85e-05	5.88e-05	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—HDAC3—metabolic syndrome X	2.84e-05	5.86e-05	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—APOC3—metabolic syndrome X	2.84e-05	5.86e-05	CbGpPWpGaD
Bortezomib—PTGS1—Metabolism—PPARG—metabolic syndrome X	2.83e-05	5.85e-05	CbGpPWpGaD
Bortezomib—PSMA1—Metabolism—AKT1—metabolic syndrome X	2.83e-05	5.84e-05	CbGpPWpGaD
Bortezomib—PSMD1—Metabolism—AKT1—metabolic syndrome X	2.81e-05	5.81e-05	CbGpPWpGaD
Bortezomib—PSMD2—Metabolism—AKT1—metabolic syndrome X	2.8e-05	5.78e-05	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism—PLA2G4A—metabolic syndrome X	2.78e-05	5.75e-05	CbGpPWpGaD
Bortezomib—PTGS1—Metabolism—INS—metabolic syndrome X	2.78e-05	5.74e-05	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—GCKR—metabolic syndrome X	2.77e-05	5.73e-05	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—LPA—metabolic syndrome X	2.77e-05	5.73e-05	CbGpPWpGaD
Bortezomib—PSMB2—Disease—IL6—metabolic syndrome X	2.77e-05	5.72e-05	CbGpPWpGaD
Bortezomib—PSMB5—Disease—IL6—metabolic syndrome X	2.77e-05	5.72e-05	CbGpPWpGaD
Bortezomib—PSMB1—Disease—IL6—metabolic syndrome X	2.77e-05	5.72e-05	CbGpPWpGaD
Bortezomib—PSMB2—Immune System—AKT1—metabolic syndrome X	2.77e-05	5.72e-05	CbGpPWpGaD
Bortezomib—PSMB1—Immune System—AKT1—metabolic syndrome X	2.77e-05	5.72e-05	CbGpPWpGaD
Bortezomib—PSMB5—Immune System—AKT1—metabolic syndrome X	2.77e-05	5.72e-05	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—GOT1—metabolic syndrome X	2.76e-05	5.7e-05	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—GGT1—metabolic syndrome X	2.76e-05	5.7e-05	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—CETP—metabolic syndrome X	2.75e-05	5.69e-05	CbGpPWpGaD
Bortezomib—PSMB1—Gene Expression—AKT1—metabolic syndrome X	2.75e-05	5.69e-05	CbGpPWpGaD
Bortezomib—PSMB5—Gene Expression—AKT1—metabolic syndrome X	2.75e-05	5.69e-05	CbGpPWpGaD
Bortezomib—PSMB2—Gene Expression—AKT1—metabolic syndrome X	2.75e-05	5.69e-05	CbGpPWpGaD
Bortezomib—PSMB8—Disease—IL6—metabolic syndrome X	2.73e-05	5.64e-05	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism—LPL—metabolic syndrome X	2.73e-05	5.64e-05	CbGpPWpGaD
Bortezomib—PSMB8—Immune System—AKT1—metabolic syndrome X	2.73e-05	5.64e-05	CbGpPWpGaD
Bortezomib—PSMB8—Gene Expression—AKT1—metabolic syndrome X	2.72e-05	5.61e-05	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—PLA2G6—metabolic syndrome X	2.69e-05	5.55e-05	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—APOA5—metabolic syndrome X	2.66e-05	5.49e-05	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—SCARB1—metabolic syndrome X	2.64e-05	5.45e-05	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—metabolic syndrome X	2.63e-05	5.43e-05	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism—APOB—metabolic syndrome X	2.62e-05	5.42e-05	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—ABCA1—metabolic syndrome X	2.62e-05	5.41e-05	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—SLC2A4—metabolic syndrome X	2.62e-05	5.41e-05	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—ABCA1—metabolic syndrome X	2.6e-05	5.37e-05	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—SLC2A4—metabolic syndrome X	2.6e-05	5.37e-05	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism—CD36—metabolic syndrome X	2.6e-05	5.36e-05	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—TGFB1—metabolic syndrome X	2.58e-05	5.32e-05	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—TGFB1—metabolic syndrome X	2.58e-05	5.32e-05	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—TGFB1—metabolic syndrome X	2.58e-05	5.32e-05	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism of lipids and lipoproteins—ALB—metabolic syndrome X	2.57e-05	5.3e-05	CbGpPWpGaD
Bortezomib—PSMA1—Signaling Pathways—IL6—metabolic syndrome X	2.56e-05	5.29e-05	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—SREBF1—metabolic syndrome X	2.56e-05	5.29e-05	CbGpPWpGaD
Bortezomib—PSMB1—Disease—AKT1—metabolic syndrome X	2.56e-05	5.28e-05	CbGpPWpGaD
Bortezomib—PSMB5—Disease—AKT1—metabolic syndrome X	2.56e-05	5.28e-05	CbGpPWpGaD
Bortezomib—PSMB2—Disease—AKT1—metabolic syndrome X	2.56e-05	5.28e-05	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism—PLA2G4A—metabolic syndrome X	2.55e-05	5.27e-05	CbGpPWpGaD
Bortezomib—PSMD1—Signaling Pathways—IL6—metabolic syndrome X	2.55e-05	5.26e-05	CbGpPWpGaD
Bortezomib—PTGS1—Metabolism—ALB—metabolic syndrome X	2.55e-05	5.26e-05	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—TGFB1—metabolic syndrome X	2.54e-05	5.24e-05	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—GOT1—metabolic syndrome X	2.54e-05	5.24e-05	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—GGT1—metabolic syndrome X	2.54e-05	5.24e-05	CbGpPWpGaD
Bortezomib—PSMD2—Signaling Pathways—IL6—metabolic syndrome X	2.54e-05	5.24e-05	CbGpPWpGaD
Bortezomib—PSMB8—Disease—AKT1—metabolic syndrome X	2.52e-05	5.21e-05	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—GOT1—metabolic syndrome X	2.52e-05	5.2e-05	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—GGT1—metabolic syndrome X	2.52e-05	5.2e-05	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism—LPL—metabolic syndrome X	2.51e-05	5.17e-05	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—HMGCR—metabolic syndrome X	2.49e-05	5.14e-05	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—GOT2—metabolic syndrome X	2.49e-05	5.14e-05	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—TRIB3—metabolic syndrome X	2.47e-05	5.11e-05	CbGpPWpGaD
Bortezomib—PTGS1—Metabolism—NOS3—metabolic syndrome X	2.44e-05	5.03e-05	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism—PPARA—metabolic syndrome X	2.41e-05	4.98e-05	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism—CD36—metabolic syndrome X	2.38e-05	4.92e-05	CbGpPWpGaD
Bortezomib—PSMA1—Signaling Pathways—AKT1—metabolic syndrome X	2.36e-05	4.88e-05	CbGpPWpGaD
Bortezomib—PSMD1—Signaling Pathways—AKT1—metabolic syndrome X	2.35e-05	4.86e-05	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—APOB—metabolic syndrome X	2.34e-05	4.84e-05	CbGpPWpGaD
Bortezomib—PSMD2—Signaling Pathways—AKT1—metabolic syndrome X	2.34e-05	4.83e-05	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism—AGT—metabolic syndrome X	2.34e-05	4.83e-05	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism—APOE—metabolic syndrome X	2.29e-05	4.73e-05	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—PLA2G4A—metabolic syndrome X	2.28e-05	4.7e-05	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism—APOA1—metabolic syndrome X	2.26e-05	4.68e-05	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—metabolic syndrome X	2.25e-05	4.64e-05	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—LPL—metabolic syndrome X	2.24e-05	4.62e-05	CbGpPWpGaD
Bortezomib—PTGS1—Metabolism—PTGS2—metabolic syndrome X	2.23e-05	4.6e-05	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—ABCA1—metabolic syndrome X	2.22e-05	4.59e-05	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—SLC2A4—metabolic syndrome X	2.22e-05	4.59e-05	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—NAMPT—metabolic syndrome X	2.22e-05	4.58e-05	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism—PPARA—metabolic syndrome X	2.21e-05	4.57e-05	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—LIPC—metabolic syndrome X	2.2e-05	4.55e-05	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—GCK—metabolic syndrome X	2.2e-05	4.55e-05	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—APOC3—metabolic syndrome X	2.19e-05	4.52e-05	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—APOB—metabolic syndrome X	2.15e-05	4.45e-05	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—GOT1—metabolic syndrome X	2.15e-05	4.44e-05	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—GGT1—metabolic syndrome X	2.15e-05	4.44e-05	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism—AGT—metabolic syndrome X	2.14e-05	4.43e-05	CbGpPWpGaD
Bortezomib—PSMB1—Metabolism—AKT1—metabolic syndrome X	2.14e-05	4.42e-05	CbGpPWpGaD
Bortezomib—PSMB2—Metabolism—AKT1—metabolic syndrome X	2.14e-05	4.42e-05	CbGpPWpGaD
Bortezomib—PSMB5—Metabolism—AKT1—metabolic syndrome X	2.14e-05	4.42e-05	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—APOB—metabolic syndrome X	2.14e-05	4.41e-05	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—CETP—metabolic syndrome X	2.13e-05	4.39e-05	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—CD36—metabolic syndrome X	2.12e-05	4.39e-05	CbGpPWpGaD
Bortezomib—PSMB8—Metabolism—AKT1—metabolic syndrome X	2.11e-05	4.36e-05	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism—APOE—metabolic syndrome X	2.1e-05	4.34e-05	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—PLA2G4A—metabolic syndrome X	2.1e-05	4.33e-05	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—PLA2G4A—metabolic syndrome X	2.08e-05	4.29e-05	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism—APOA1—metabolic syndrome X	2.08e-05	4.29e-05	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—LPL—metabolic syndrome X	2.06e-05	4.25e-05	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—LPL—metabolic syndrome X	2.04e-05	4.21e-05	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—SCARB1—metabolic syndrome X	2.04e-05	4.2e-05	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism—PPARG—metabolic syndrome X	2e-05	4.12e-05	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—SREBF1—metabolic syndrome X	1.98e-05	4.08e-05	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—PPARA—metabolic syndrome X	1.98e-05	4.08e-05	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism—INS—metabolic syndrome X	1.96e-05	4.04e-05	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—CD36—metabolic syndrome X	1.95e-05	4.04e-05	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—IL6—metabolic syndrome X	1.94e-05	4.01e-05	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—IL6—metabolic syndrome X	1.94e-05	4.01e-05	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—IL6—metabolic syndrome X	1.94e-05	4.01e-05	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—CD36—metabolic syndrome X	1.94e-05	4e-05	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—HMGCR—metabolic syndrome X	1.92e-05	3.97e-05	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—GOT2—metabolic syndrome X	1.92e-05	3.97e-05	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—IL6—metabolic syndrome X	1.91e-05	3.95e-05	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—AGT—metabolic syndrome X	1.91e-05	3.95e-05	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—APOE—metabolic syndrome X	1.87e-05	3.87e-05	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—APOA1—metabolic syndrome X	1.85e-05	3.83e-05	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism—PPARG—metabolic syndrome X	1.83e-05	3.78e-05	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—APOB—metabolic syndrome X	1.82e-05	3.77e-05	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—PPARA—metabolic syndrome X	1.82e-05	3.75e-05	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—PPARA—metabolic syndrome X	1.8e-05	3.72e-05	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism—INS—metabolic syndrome X	1.79e-05	3.7e-05	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism—ALB—metabolic syndrome X	1.79e-05	3.7e-05	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—AKT1—metabolic syndrome X	1.79e-05	3.7e-05	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—AKT1—metabolic syndrome X	1.79e-05	3.7e-05	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—AKT1—metabolic syndrome X	1.79e-05	3.7e-05	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—PLA2G4A—metabolic syndrome X	1.78e-05	3.67e-05	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—AKT1—metabolic syndrome X	1.77e-05	3.65e-05	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—AGT—metabolic syndrome X	1.76e-05	3.63e-05	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—AGT—metabolic syndrome X	1.74e-05	3.6e-05	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—LPL—metabolic syndrome X	1.74e-05	3.6e-05	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—APOE—metabolic syndrome X	1.72e-05	3.56e-05	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism—NOS3—metabolic syndrome X	1.72e-05	3.54e-05	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—ABCA1—metabolic syndrome X	1.71e-05	3.54e-05	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—SLC2A4—metabolic syndrome X	1.71e-05	3.54e-05	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—APOE—metabolic syndrome X	1.71e-05	3.53e-05	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—APOA1—metabolic syndrome X	1.7e-05	3.52e-05	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—APOA1—metabolic syndrome X	1.69e-05	3.49e-05	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—GGT1—metabolic syndrome X	1.66e-05	3.43e-05	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—GOT1—metabolic syndrome X	1.66e-05	3.43e-05	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—CD36—metabolic syndrome X	1.66e-05	3.42e-05	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism—ALB—metabolic syndrome X	1.64e-05	3.4e-05	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—PPARG—metabolic syndrome X	1.63e-05	3.37e-05	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—INS—metabolic syndrome X	1.6e-05	3.31e-05	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism—NOS3—metabolic syndrome X	1.57e-05	3.25e-05	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism—PTGS2—metabolic syndrome X	1.57e-05	3.24e-05	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—PPARA—metabolic syndrome X	1.54e-05	3.18e-05	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—PPARG—metabolic syndrome X	1.5e-05	3.1e-05	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—AGT—metabolic syndrome X	1.49e-05	3.08e-05	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—PPARG—metabolic syndrome X	1.49e-05	3.07e-05	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—INS—metabolic syndrome X	1.47e-05	3.04e-05	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—ALB—metabolic syndrome X	1.47e-05	3.03e-05	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—APOE—metabolic syndrome X	1.46e-05	3.02e-05	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—INS—metabolic syndrome X	1.46e-05	3.02e-05	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—APOA1—metabolic syndrome X	1.44e-05	2.98e-05	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism—PTGS2—metabolic syndrome X	1.44e-05	2.97e-05	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—APOB—metabolic syndrome X	1.41e-05	2.91e-05	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—NOS3—metabolic syndrome X	1.4e-05	2.9e-05	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—PLA2G4A—metabolic syndrome X	1.37e-05	2.83e-05	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—ALB—metabolic syndrome X	1.35e-05	2.79e-05	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—LPL—metabolic syndrome X	1.34e-05	2.78e-05	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—ALB—metabolic syndrome X	1.34e-05	2.76e-05	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—NOS3—metabolic syndrome X	1.29e-05	2.67e-05	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—PTGS2—metabolic syndrome X	1.28e-05	2.65e-05	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—NOS3—metabolic syndrome X	1.28e-05	2.64e-05	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—CD36—metabolic syndrome X	1.28e-05	2.64e-05	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—PPARG—metabolic syndrome X	1.27e-05	2.63e-05	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—INS—metabolic syndrome X	1.25e-05	2.58e-05	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—PPARA—metabolic syndrome X	1.19e-05	2.45e-05	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—PTGS2—metabolic syndrome X	1.18e-05	2.44e-05	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—PTGS2—metabolic syndrome X	1.17e-05	2.42e-05	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—AGT—metabolic syndrome X	1.15e-05	2.38e-05	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—ALB—metabolic syndrome X	1.14e-05	2.36e-05	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—APOE—metabolic syndrome X	1.13e-05	2.33e-05	CbGpPWpGaD
Bortezomib—PTGS1—Metabolism—AKT1—metabolic syndrome X	1.12e-05	2.31e-05	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—APOA1—metabolic syndrome X	1.11e-05	2.3e-05	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—NOS3—metabolic syndrome X	1.09e-05	2.26e-05	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—PTGS2—metabolic syndrome X	1e-05	2.07e-05	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—PPARG—metabolic syndrome X	9.82e-06	2.03e-05	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—INS—metabolic syndrome X	9.63e-06	1.99e-05	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—ALB—metabolic syndrome X	8.83e-06	1.82e-05	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—NOS3—metabolic syndrome X	8.44e-06	1.74e-05	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism—AKT1—metabolic syndrome X	7.89e-06	1.63e-05	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—PTGS2—metabolic syndrome X	7.72e-06	1.59e-05	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism—AKT1—metabolic syndrome X	7.23e-06	1.49e-05	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—AKT1—metabolic syndrome X	6.45e-06	1.33e-05	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—AKT1—metabolic syndrome X	5.94e-06	1.23e-05	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—AKT1—metabolic syndrome X	5.89e-06	1.22e-05	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—AKT1—metabolic syndrome X	5.03e-06	1.04e-05	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—AKT1—metabolic syndrome X	3.88e-06	8.02e-06	CbGpPWpGaD
